Awareness of Bisphosphonate Use and Its Dental Complications among the Dental Practitioners

1Gauri Kokane, 2Sunil Sidana, 3Jyotsna Galinde, 4Imran Khalid

ABSTRACT

Objectives: To assess the awareness, among dental practitioners, of the use of bisphosphonates (BP) and its complications related to dental extractions as well as to outline protocol for its prevention and management.

Materials and methods: A cross-sectional descriptive study was carried out in department of oral and maxillofacial surgery, MGM Dental College and Hospital, Kamothe, Navi Mumbai, in December 2013. Data collection was carried out by self-administered questionnaire distributed among interns, postgraduate students and staff members at the hospital.

Results: Total of 159 people were included in to the study. Out of which 95 were interns, 25 were postgraduate students and 39 were staff members. Four out of 39 staff members, six postgraduate students out of 25 and 18 out of 99 interns were unaware of the trade name of drug alendronate as Fosamax. Eight staff out of 39, six postgraduate students of 25 and 23 interns out of 95 were unaware of term BRONJ. Thirty-three out of 39 staff, 20 out of 25 postgraduate student and 81 out of 95 interns were aware of clinical use of BP. Thirty-eight out of 39 staff, 23 out of 25 postgraduate student and 93 out of 95 interns were familiar with BP. Fourteen out of 39 staff, 20 out of 25 postgraduate student and 81 out of 95 interns were aware of guidelines on treating patients on BP. Thirty-seven out of 39 staff, four out of 25 postgraduate students and 21 out of 95 interns out of 95 were unaware of term BRONJ. Thirty-three out of 39 staff, six postgraduate students out of 25 and 18 out of 99 interns were unaware of the trade name of drug alendronate as Fosamax.

Conclusion: There is a lack of complete awareness about BP use, its dental complications and prevention and treatment strategies for BP-related osteoradionecrosis of jaws. Bisphosphonates and its related dental complications and management should be included in the undergraduate dental curriculum.

Keywords: BRONJ, Bisphosphonates, Osteoradionecrosis, Dental.


Source of support: Nil

Conflict of interest: None

INTRODUCTION

Bisphosphonates (BP) are primarily used in the treatment and management of cancer-related conditions, including hypercalcemia of malignancy, skeletal-related events associated with bone metastases in the context of solid tumors, such as breast cancer, prostate cancer and lung cancer, and management of lytic lesions in the setting of multiple myeloma. Also, used in prevention and treatment of bone fragility diseases, like the osteitis deformans ('Paget's disease of bone'), primary hyperparathyroidism, osteogenesis imperfecta, fibrous dysplasia, and other conditions that feature bone fragility, such as osteoporosis, osteopenia, etc.1 Bisphosphonates do not improve cancer-specific survival, but it has a significant positive effect on the quality of life for patients with advanced cancer involving the skeleton.

Bisphosphonate-related osteoradionecrosis of jaws (BRONJ) is one of the major complications of BS therapy. In 2003, Marx reported BRONJ or bisphosphonate-induced osteonecrosis of the jaw (BIONJ), as a side-effect of BP treatment.2 BRONJ lesions are defined as exposed necrotic bone without evidence of healing for at least 8 weeks in the maxillofacial area in patients with a history of BP use without a history of head and neck irradiation.3 An incidence of 1 in 140,000 person life years of exposure associated with the orally administered drugs was originally based on BRONJ cases reported to pharmaceutical companies. The risk of developing BON increased more than four-fold when individuals underwent a dental extraction. It is necessary to create the awareness among dental practitioners and budding dentists regarding the BRONJ, its prevention and treatment protocol. Purpose of this study is to assess the awareness of dentists regarding BP and its dental-related complications and to outline the prevention and treatment protocol. This study was carried out in MGM Dental College and Hospital, Kamothe, Navi Mumbai, in December 2013.

MATERIALS AND METHODS

Interns, Postgraduate students and staff members of MGM Dental College and Hospital were included in the study. Questionnaire was designed to assess the awareness with regards to BP use, its complications and management. A total of 159 individuals participated in
the study, out of which 95 were interns, 25 were postgraduate students and 39 were staff members from various departments (oral medicine, radiology and diagnosis, oral pathology, periodontics, prosthodontics, orthodontics, pedodontics, oral and maxillofacial surgery).

RESULTS
A total of 159 people were included in to the study, out of which 39 were staff, 25 were postgraduate students, and 95 were interns. Four out of 39 staff members (10.25%), six postgraduate students out of 25 (24%) and 18 out of 99 (18.18%) interns were unaware of trade name of drug alendronate as Fosamex. Eight staff out of 39 (20.51%), six postgraduate students of 25 (24%) and 23 interns of 95 (24.21) were unaware of term BRONJ. Thirty-three out of 39 (84.61%), 20 out of 25 (80%) and 81 out of 95 (85.26%) were aware of clinical use of BP. Thirty-eight out of 39 (97.23%), 23 out of 29 (79.31%) and 93 out of 95 (97.89%) were familiar with BP. Fourteen out of 39 (35.89%) staff, 3 out of 25 (10.34%) postgraduate students and 25 out of 95 (26.31%) interns were aware of guidelines on treating patients on BP. Thirty seven out of 39 (94.87%) staff, 4 out of 25 (16%) postgraduate students and 21 out of 95 (22.10%) interns have asked patients about history of BP use (Graphs 1 to 8).

DISCUSSION
Bisphosphonates are said to inhibit osteoclastic bone resorption and bone remodeling by inhibiting osteoclast differentiation and function and promoting apoptosis.\textsuperscript{4-9} Since the bone turnover rate is highest in maxilla and mandible, these are the most vulnerable sites for its occurrence.\textsuperscript{10,11} Other factor in pathophysiology is inhibition of angiogenesis. Osteonecrosis itself is a form of avascular necrosis, so inhibition of angiogenesis is thought to be responsible for occurrence of osteonecrosis.

Infection and inflammation is also thought to be a cause. In the biopsy specimen, actinomyces species was found.\textsuperscript{12}

In this study, 33 out of 39 (84.61%), 20 out of 25 (68.96%) and 81 out of 95 (85.26%) were aware of clinical use of BP. Patients with metastatic disorders and hypercalcemia are treated with IV BP.\textsuperscript{2} Postmenopausal women presenting osteoporosis or osteopetrosis are prescribed with oral BP. It becomes important to take necessary precautions in these patients before undergoing any major or minor oral surgical procedure. Pamidronate, zoledronic acid are injectable BP and alendronate and risidronate are oral formulations.\textsuperscript{2} The typical presentation of disease is of nonhealing extraction socket or exposed jawbone with progression to sequestrum formation associated with localized swelling and purulent discharge.\textsuperscript{4} Diagnostic criterion is according to AAOMS definition, clinical and radiological findings, also biopsy, can be taken to rule out malignancy.\textsuperscript{2}

It is important to understand that patients at risk of, or with established, BRONJ can also present with other common clinical conditions not to be confused with BRONJ. In this study, eight staff out of 39, six postgraduate students of 25 and 23 interns of 95 were unaware of term BRONJ and its presentation. Commonly misdiagnosed conditions can include, but are not limited to, alveolar osteitis, sinusitis, gingivitis/periodontitis, caries, periapical pathologic findings, and temporomandibular joint disorders.

CLINICAL PRESENTATION
The site of involvement may be an area of prior trauma, such as an extraction or irritation from a dental prosthesis, although spontaneous osteonecrosis also can occur. The extent of symptoms and clinical disease shows varied presentation despite of similar disease processes,
biphasphate dose and treatment duration. A staging system was based on these observations, developed that facilitates the clinical stratification of this disease process and guides treatment strategies.

- **Stage 0**: Signs and symptoms short of exposed necrotic bone that might indicate a histologic necrosis or a prenecrotic state.
- **Stage 1**: Exposed necrotic bone that is asymptomatic.

**Graph 3**: Bisphosphonate is used to treat

**Graph 4**: Have you heard about bisphosphonates

**Graph 5**: Are you aware of any guideline for treating patients on bisphosphonates

**Graph 6**: Did you in the past ever ask your patients for history of bisphosphonates before dental extractions

**Graph 7**: What is the side-effect of bisphosphonate in patients undergoing extraction

**Graph 8**: Can you prevent BRONJ in dental patients undergoing extractions
• **Stage 2**: Exposed, necrotic bone associated with pain and adjacent or regional soft-tissue involvement.
• **Stage 3**: Necrotic bone with associated pain and adjacent or regional soft-tissue infection and a pathologic fracture, extraoral fistula or osteolysis extending to the inferior border.

**MANAGEMENT PROTOCOL**

• **For prevention of BRONJ**: Every patient who is going to start on BP therapy should be scanned for dental foci of infection and the focus if present should be attended and solved before the therapy starts, this will prevent the occurrence of BRONJ. Out of 39 staff (94.86%), four out of 25 (16%) postgraduate students and 21 out of 95 (22.10%) interns have asked patients about history of BP use. Patients should be looked for caries, periodontal disease; any minor oral surgical treatment should be performed well before the BP therapy initiation. Nonrestorable teeth and teeth with poor prognosis should be extracted before hand patients with complete or partial dentures should be looked for areas of irritation over mucosa and mainly in lingual flange region. Early dental screening and initiation of appropriate treatment has found to reduce the incidence BRONJ. It is important to find out potential sites of infection along with the focus of acute infection in order to prevent further sequel which could get exacerbated when therapy is initiated. It is important to educate the patients regarding oral hygiene and regular dental check-up. Patients are asked to report immediately if any pain, swelling or exposed bone. Dimopoulos found a statistically significant, almost threefold reduction in the incidence of osteonecrosis in patients when preventive measures were applied.

Drug holiday is another concept to prevent the risk of BRONJ. It involves temporary cessation of therapy before the invasive dental procedure, if systemic condition permits. American Association of Oral and Maxillofacial Surgeons (AAOMS) (2009) recommends discontinuing of BP therapy 3 months prior and 3 months after the invasive dental procedure. Patients having BP exposure for more than 4 years are at higher-risk for BRONJ, therefore, drug holiday is beneficial in such cases. It is advised to continue BP therapy in patients with BP exposure of less than 2 years.

They note that since 50% of serum BP undergoes renal excretion the major reservoir of BP is the osteoclast whose life span is 2 weeks. Thus, the majority of free BP within the serum would be extremely low 2 months following the last dose of an oral BP and a 2-month drug-free period should be adequate prior to an invasive dental procedure. Patients physician should be contacted prior to any dental procedure with regards to discontinuation of BP drugs.

**TREATMENT OF BRONJ**

**Patients with BRONJ**

The treatment objectives for patients with an established diagnosis of BRONJ are to eliminate pain, control infection of the soft and hard tissue, and minimize the progression or occurrence of bone necrosis. Patients benefit from the use of oral antimicrobial rinses, such as chlorhexidine 0.12%. No surgical treatment is indicated.

• **Stage 1**: Patients benefit from the use of oral antimicrobial rinses in combination with antibiotic therapy. It is hypothesized that the pathogenesis of BRONJ may be related to factors adversely influencing bone remodeling. Additionally, BRONJ is not due to a primary infectious etiology. Most of the isolated microbes have been sensitive to the penicillin group of antibiotics. Quinolones, metronidazole, clindamycin, doxycycline and erythromycin have been used with success in those patients who are allergic to penicillin. Microbial cultures should also be analyzed for the presence of actinomycetes species of bacteria. If this microbe is isolated, the antibiotic regimen should be adjusted accordingly. In some refractory cases, patients may require combination antibiotic therapy, long-term antibiotic maintenance, or a course of intravenous antibiotic therapy.

• **Stage 2**: These patients benefit from the use of oral antimicrobial rinses with regards to discontinuation of BP drugs. They note that since 50% of serum BP undergoes renal excretion the major reservoir of BP is the osteoclast whose life span is 2 weeks. Thus, the majority of free BP within the serum would be extremely low 2 months following the last dose of an oral BP and a 2-month drug-free period should be adequate prior to an invasive dental procedure. Patients physician should be contacted prior to any dental procedure with regards to discontinuation of BP drugs.

**TREATMENT OF BRONJ**

**Patients with BRONJ**

The treatment objectives for patients with an established diagnosis of BRONJ are to eliminate pain, control infection of the soft and hard tissue, and minimize the progression or occurrence of bone necrosis. Patients benefit from the use of oral antimicrobial rinses, such as chlorhexidine 0.12%. No surgical treatment is indicated.

• **Stage 1**: Patients benefit from the use of oral antimicrobial rinses in combination with antibiotic therapy. It is hypothesized that the pathogenesis of BRONJ may be related to factors adversely influencing bone remodeling. Additionally, BRONJ is not due to a primary infectious etiology. Most of the isolated microbes have been sensitive to the penicillin group of antibiotics. Quinolones, metronidazole, clindamycin, doxycycline and erythromycin have been used with success in those patients who are allergic to penicillin. Microbial cultures should also be analyzed for the presence of actinomycetes species of bacteria. If this microbe is isolated, the antibiotic regimen should be adjusted accordingly. In some refractory cases, patients may require combination antibiotic therapy, long-term antibiotic maintenance, or a course of intravenous antibiotic therapy.

• **Stage 2**: These patients benefit from the use of oral antimicrobial rinses with regards to discontinuation of BP drugs. They note that since 50% of serum BP undergoes renal excretion the major reservoir of BP is the osteoclast whose life span is 2 weeks. Thus, the majority of free BP within the serum would be extremely low 2 months following the last dose of an oral BP and a 2-month drug-free period should be adequate prior to an invasive dental procedure. Patients physician should be contacted prior to any dental procedure with regards to discontinuation of BP drugs.
CONCLUSION
There is lack of complete awareness regarding the side effects and guidelines for management of BP-related osteoradionecrosis of the jaws. It is a very important to find out patients who are at risk of BRONJ or who have developed the same. Meticulous examination and treatment is the need. So, it is very important to develop awareness regarding BP use and its complications among the dental professionals.

REFERENCES